Gopalakrishna Harish, Asif Bilal, Rai Anjali, Conjeevaram Hari S, Mironova Maria, Kleiner David E, Freeman Alexandra F, Heller Theo
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Case Rep Gastroenterol. 2024 Feb 1;18(1):49-57. doi: 10.1159/000536117. eCollection 2024 Jan-Dec.
Prolidase deficiency is a rare autosomal recessive disorder caused by variants in the gene. Patients usually have multi-organ involvement and a wide range of clinical features including recurrent skin ulcers, dysmorphic facial features, recurrent infections, intellectual disability, and splenomegaly. Studies have shown that patients with prolidase deficiency may have hepatic manifestations including hepatomegaly and abnormal liver enzymes. However, there is no detailed description of liver disease in this patient population.
Here, we present 3 patients with prolidase deficiency with varying extents of hepatic involvement.
Prolidase deficiency patients with liver disease should be followed up long term to understand more about the pathophysiology and the impact of liver disease on long-term outcomes.
脯氨酰肽酶缺乏症是一种由该基因变异引起的罕见常染色体隐性疾病。患者通常有多器官受累以及广泛的临床特征,包括复发性皮肤溃疡、面部畸形、反复感染、智力残疾和脾肿大。研究表明,脯氨酰肽酶缺乏症患者可能有肝脏表现,包括肝肿大和肝酶异常。然而,目前尚无关于该患者群体肝脏疾病的详细描述。
在此,我们报告3例不同程度肝脏受累的脯氨酰肽酶缺乏症患者。
患有肝脏疾病的脯氨酰肽酶缺乏症患者应长期随访,以更多地了解其病理生理学以及肝脏疾病对长期预后的影响。